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Summary
Real-time quantitative polymerase chain reaction (qPCR) has been exten-
sively validated for the detection of minimal residual disease (MRD) in acute
myeloid leukaemia (AML). Meanwhile, multicolour flow cytometry (MFC)
has received less attention because the so-called leukaemia-associated
immunophenotypes (LAIPs) are generally of lower sensitivity and specificity,
and prone to change during therapy. To improve MRD assessment by MFC,
we here evaluate the combination of human Myeloid Inhibitory C-type Lec-
tin (hMICL, also termed C-type lectin domain family 12, member A,
CLEC12A) and CD 123 (also termed interleukin-3 receptor alpha, IL3RA) in
combination with CD34 and CD117 (KIT), as an MRD assay in pre-clinical
and clinical testing in 69 AML patients. Spiking experiments revealed that the
assay could detect MRD down to 104 in normal bone marrow with sensitivi-
ties equalling those of validated qPCR assays. Moreover, it provided at least
one MFC MRD marker in 62/69 patients (90%). High levels of hMICL/
CD123 LAIPs at the post-induction time-point were a strong prognostic mar-
ker for relapse in patients in haematological complete remission (P < 0001).
Finally, in post induction samples, hMICL/CD123 LAIPs were strongly corre-
lated (r = 0676, P = 00008) to applied qPCR targets. We conclude the
hMICL/CD123-based MFC assay is a promising MRD tool in AML.
Keywords: acute myeloid leukaemia, flow cytometry, minimal residual
disease, quantitative polymerase chain reaction, leukaemia-associated
immunophenotype.
The majority of curatively treated acute myeloid leukaemia
(AML) patients will experience a relapse, although deemed
being in complete remission (CR) by standard diagnostic cri-
teria (Estey & D€ohner, 2006). This is caused by the presence
and outgrowth of sustaining leukaemic stem cells (LCSs) in
the bone marrow (BM), termed minimal residual disease
(MRD) (Bachas et al, 2012). Although the translation of
some MRD assays into therapeutic decision-making has been
accomplished, especially in acute lymphoblastic leukaemia
(ALL), routinely prospective risk stratification in AML based
on MRD monitoring is marred by lack of standardized assays
and thresholds. Additionally, formal proof supporting pre-
emptive intervention of MRD-positive AML patients is still
sparse (Paietta, 2012a,b; Vora et al, 2013).
The real-time quantitative polymerase chain reaction
(qPCR) is the most sensitive and specific molecular MRD
detection method in AML, employing fusion transcripts and
over-expressed and mutated genes with sensitivities ranging
from 102 to 106 and is applicable in approximately 60% of
patients (Grimwade et al, 2009, 2010a; Hokland et al, 2012).
By contrast, MRD detection by multicolour flow cytometry
(MFC) is faster, determines accurately the number of leukae-
mic cells, and is applicable to virtually all AML patients with
sensitivities ranging from 102 to 104 in most cases (Buccisa-
no et al, 2012; Dinardo & Luger, 2012). The MFC strategy
relies upon detection of so-called leukaemia-associated im-
munophenotypes (LAIPs), which are absent or only rarely
present in normal BM. Thus, advantage is taken of aberrations
in antigen expression, such as lack of expression, cross-lineage
expression, over-expression, and asynchronous expression,
usually in combination with abnormal light scatter patterns of
leukaemic cells (Al-Mawali et al, 2008; Ossenkoppele et al,
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2011). This approach, however, requires the availability of a
comprehensive panel of antibodies at the initial diagnosis for
identification of optimal LAIP combinations. In addition, the
heterogeneity of AML cells within each patient sample can
cause a selective shift in immunophenotype during cytoreduc-
tion, which may yield false negative MRD results (Kern et al,
2010a). Moreover, LAIPs are usually identified by the expres-
sion of CD34 on leukaemic cells, even though up to 30% of
AML cases are CD34- (Bonnet, 2001; Feller et al, 2004;
Al-Mawali et al, 2009). A novel approach within MRD assess-
ment by MFC aims at enumerating LSCs rather than the whole
blast population by quantification of aberrant antigen expres-
sion on CD34+ CD38- stem cells (van Rhenen et al, 2007a).
However, this approach also fails in cases of CD34- AML as
the remaining CD34 + CD38- cells in such patients are usually
of normal origin (van der Pol et al, 2003; Taussig et al, 2010).
Recently, we have identified the human Myeloid Inhibi-
tory C type-like Lectin (hMICL) (also known as CLEC12A or
CLL-1) as a stable and reliable AML antigen expressed in
90% of diagnostic AML samples (Larsen et al, 2012). Addi-
tionally, we found that CD123 (also known as interleukin 3a
receptor, IL3RA) is widely, but not exclusively, expressed in
AML. Importantly, both hMICL and CD123 had high and
conserved antigen expression in 23/23 paired diagnostic/
relapse samples, confirming that antigenic shift is, at most, a
minor problem with these antigens (Larsen et al, 2012).
Finally, hMICL and CD123 have been reported to be robust
markers for LSCs and thus possible targets in antibody medi-
ated anti-leukaemia treatment (van Rhenen et al, 2005,
2007b; Majeti, 2010).
In this study we have evaluated the MRD potential of a
single tube MFC experiment employing hMICL and CD123
in combination with CD45 (also known as PTPRC), CD34,
CD117 (also known as KIT), and CD14. The rationale for
employing CD45, CD34, and CD117 is that these antigens
have proven the most frequent backbone markers in AML
and consequently included the add on of hMICL and CD123
(Al-Mawali et al, 2009; van Dongen et al, 2012). We initially
performed a series of paralleled MFC and qPCR spiking
experiments and then tested the assay in a prospective study
encompassing 69 patients. Taken together, this data set
shows that the hMICL/CD123 MFC assay is a valuable addi-
tion to MRD monitoring with sensitivities approaching those
obtained by qPCR assays in a simplified MFC-based setting
covering more than 90% of AML patients.
Materials and methods
Patient samples
All sampling was conducted with informed patient consent
and in accordance with the Declaration of Helsinki. The
study was approved by the local Ethics Committee. A total
of 69 prospectively accrued diagnostic AML samples were
obtained from the Department of Haematology, Aarhus
University Hospital, from June 2009 to June 2011. A total of
40 patients were treated with curative intent. Of these, 21
patients were evaluable for post-induction response by paral-
leled MFC and qPCR MRD quantification (Table I). Normal
BM from healthy volunteers (n = 12) and regenerating BM
from ALL patients (n = 7) obtained at day 29 were used as
control samples for sensitivity studies and for generation of
internal standard references. The ALL patients included were
all diagnosed at our institution and enrolled in the NOPHO
2008 study. In this protocol, patients were systematically sub-
jected to response evaluation post-induction at day 29. Nor-
mal donor CD3+ T-cells for spiking experiments were
isolated from peripheral blood from two healthy donors
using the immunomagnetic EasySep CD3 Positive Selection
Kit (StemCell Technologies Grenoble, France).
Flow cytometry
Standard four-colour MFC was performed on erythrocyte-
lysed whole BM with monoclonal antibody (MoAb)
combinations for diagnostic purpose, LAIP identification and
monitoring of MRD in follow-up samples. An additional
Table I. Patient characteristics.
Characteristic Value
Sex, number of patients (male/female) 69 (41/28)
Age, years (median; range) 655 (7–94)
Total leucocytes x 109/l(median; range) 43 (01–312)
Bone marrow blasts at diagnosis% (median; range) 58 (20-97)
Karyotype (n)*
Favourable 4
Unfavourable 11
Intermediate 47
Not done 7
Molecular MRD target
WT1 36
PML-RARA 1
RUNX1-RUNX1T1 2
CBFB-MYH11 1
Negative 8
Not done (age > 70 years) 22
CD34 expression**
CD34 18
CD34+ 41
Treated with curative intent 40
Available paired MFC/qPCR samples post induction 21
MRD, minimal residual disease; MFC, multicolour flow cytometry;
qPCR, real-time quantitative polymerase chain reaction.
*’Favourable’, cases with t(8;21), t(15;17), or inv(16)/t(16;16); ‘unfa-
vourable’, cases with complex cytogenetic changes (>3 unrelated
abnormalities), 5, add(5q)/del(5q), 7/add(7q), t(6;11), t(10;11),
t(9;22), 17, abn(17p) with other changes, 3q abnormalities exclud-
ing t(3;5), inv(3)/t(3;3); and ‘intermediate’, cases with normal karyo-
type and other noncomplex. (Grimwade et al, 2010b).
**Applying a cut off of 1% CD34+ blast cells.
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tube with a six-colour combination including MoAbs against
hMICL, CD123, CD45, CD34, CD117 and CD14 was run in
all cases. All combinations of MoAbs and their purveyors are
given in Table S1. Data acquisition was performed on a
Canto II [BD Biosciences, San Jose, CA, USA (BD)] and
analysed using BD FACSDiva software (BD). Apoptotic and
dead cells were deselected using Annexin V and 7-Aminoacti-
nomycin D (7-AAD; BD). A minimum of 250 000 live
CD45+ events was acquired, resulting in a theoretical maxi-
mum sensitivity of at least 0008% in these experiments tak-
ing into account that a cluster of 20 events is needed for
clear definition of a cell population (Buccisano et al, 2009).
Identification of LAIPs, calculations based on MFC
analyses and Gating Strategy
Leukaemic cells were identified based on low expression of
CD45 and low side scatter (SSC) properties (CD45low/
SSClow) (Borowitz et al, 1993; Lacombe et al, 1997). As dif-
ferentiated monocytes express both hMICL and CD123,
CD14 de-selection was performed except for cases with
CD14+ AML. Potential LAIP populations were identified by
the expression of combinations of hMICL, CD123, CD34,
and CD117 and quantified in normal and leukaemic BM,
applying the same stringent gating strategy in all samples. A
threshold of at least 5% LAIP positive cells was set for a
given LAIP combination to be denoted as positive. All LAIP
positive cells were back-gated to FSC/SSC plots to ensure
homogeneous scatter properties. Comparisons between AML
and control samples allowed for the discovery of an ‘empty
space’, defined as regions devoid of normal BM cells in an
hMICL/CD123 dot plot. The gating strategy used and repre-
sentative examples of LAIPs are depicted in Fig 1.
In order to estimate the degree of reduction in leukaemic
mass detectable by the present approach, the logarithmic dif-
ference (LD) between AML and normal BM samples was cal-
culated as the frequency of a LAIP in AML BM divided by
that of the LAIP in normal and regenerating BM. The maxi-
mal LD observed was used for selection of the most optimal
LAIP in a given patient. For comparison of MFC MRD val-
ues to qPCR values, these were normalized and diagnostic
values were set at 1.
Dilution experiments of in vitro sensitivity of
hMICL/CD123 LAIPs
Dilution experiments were employed to test the theoretical
maximal sensitivity in vitro. To this end, BM from two dif-
ferent AML patients were admixed with purified T-lympho-
cytes from normal donors. Secondly, BM from eight AML
patients was admixed with normal BM to approximate the
sensitivity of the assay in the clinical setting. In parallel, in
five of the patients, in whom at least one molecular marker
suitable for quantification by qPCR was present, spiking of
RNA from AML cells in normal BM was performed. The
dilution ranged from 1:1 to 1:216 (in lymphocyte dilutions
1:1 to 1:218) for each experiment. A minimum of 500,000
events was acquired resulting in a theoretical maximal
sensitivity of at least 0004%.
Real-time quantitative PCR
RNA purification and cDNA synthesis was performed as pre-
viously reported (Beillard et al, 2003; Østergaard et al, 2004).
Levels of PML-RARA, RUNX1-RUNX1T1, CBFB-MYH11,
and WT1 over expression were analysed by TaqMan qPCR
on an Mx3000P PCR or Mx3005P PCR thermocycler (Strata-
gene, La Jolla, CA, USA). All reactions were run on mononu-
clear cells in triplicates and data normalized to the mean of
the two housekeeping genes c-abl oncogene 1, non-receptor
tyrosine kinase (ABL1) and b-2-microglobulin (B2M). At
diagnosis, normalized expression levels were set at one. Pri-
mer pairs and probes are given in Table S2. Sensitivities and
frequencies of the respective aberrations are given in (Gabert
et al, 2003).
Statistics
The association between qPCR and MFC values was quanti-
fied calculating the Spearman correlation coefficient. The
Kaplan-Meier method was used to estimate the distribution
of relapse-free survival (RFS), defined as the time between
day 1 of treatment and date of relapse, censored at last day
of contact. Univariate associations between MRD groups and
relapse were tested using log-rank test. Two-tailed P-values
<005 were considered significant.
Results
In vitro sensitivity of hMICL/CD123 LAIPs
The theoretical sensitivity of the hMICL/CD123 was deter-
mined by performing two-fold dilutions of AML cells in highly
purified T-cells, the latter acting as true hMICL-/CD123-/
CD34-/CD117- control cells (Fig 2A). The sensitivity of the
assay was calculated from the plateau-phase at of the titration
curve and was at least 1:4,500 for the hMICL+ CD123 + and
at least 1:30,000 for CD34+ hMICL+CD123+ LAIP.
The sensitivity of the hMICL/CD123 assay in a setting resem-
bling that of clinical testing was evaluated. Dilution experiments
for qPCR-positive patients are shown in Fig 2B–F, and the
three patients without molecular MRD markers are displayed in
Fig S1. The detection limits of MFC ranged from 102 to below
104. The spiking LAIP assessments with hMICL/CD123
combinations completely paralleled qPCR quantification for
molecularly positive patients. However, for cases with fusion
transcript-positive AML the qPCR methods were more sensitive
than MFC. On the other hand, in one case (Fig 2B ‘empty
space’) the MFC approach was almost as sensitive as the
PML-RARA qPCR assay, reaching below the 104 level.
A. S. Roug et al
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Fig. 2. Two-fold dilution series of hMICL+ blasts admixed to T-cells and normal bone marrow with paralleled qPCR results. Dotted lines repre-
sent sensitivity of real-time quantitative polymerase chain reaction (qPCR) methods and background of hMICL/CD123 cells from the donor used
in each experiment. (A) Titration of hMICL+ cells on a negative background of purified T-cells. Axes in (A) are representative of all experiments
A-F. (B) The hMICL/CD123-based leukaemia-associated immunophenotype (LAIP) titrated in a donor with high WT1 background. (C+D) Dilu-
tion series of hMICL/CD123-based LAIPs and paralleled qPCR results of PML-RARA and WT1 from two t(15;17) patients. (E-F) Dilution series
of hMICL/CD123-based LAIPs and paralleled qPCR results for CBFB-MYH11 + and WT1 from two inv(16) positive patients. ND, normal
donor.
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Fig 1. Gating strategy and examples of defined hMICL/CD123 LAIPs. Gating strategy detailed and exemplified in normal bone marrow (BM)
and acute myeloid leukaemia (AML) BM samples. The frequencies of leukaemia-associated immunophenotype (LAIP)+ cells within the normal
BM are given as median values from all normal samples analysed. Each individual LAIP was analysed in the same way in both AML cases and
normal BM. (A) The progenitor population in normal BM and the blast population in AML were characterized by low expression of CD45
and low side scatter (CD45low/SSClow). Granulocytes were excluded based on SSC properties. (B) Monocytes in the CD45low/SSClow were
excluded using CD14 staining. (C) hMICL+/CD34+ cells were back-gated into a forward scatter (FSC)/SSC plot in order to ensure homogeneous
scatter properties of the population defined (D). Back-gating into a FSC/SSC plot was performed for all LAIPs defined. The
hMICL+CD123 + CD117 + population in normal BM (E–F) and in a CD34- AML patient (G–H). The hMICL+CD123 + CD34 + population
in normal BM (I+J) and in an AML patient (K-L). The empty space region, defined as CD34+/CD123+/hMICL- cells, in normal BM (M+N) and
in an AML patient (O-P)
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Frequencies of hMICL/CD123-based LAIPs in AML and
in normal and regenerating bone marrow
We delineated the value of hMICL/CD123 combinations for
MRD detection by comparing BM from AML patients with
normal and regenerating BM. The LAIP populations defined,
the number of LAIPs identified, and the number of LAIP
positive patients by application of the hMICL/CD123 to the
CD45/CD34/CD117 backbone are detailed in Table II. A
total of 11 populations fulfilling LAIP criteria were identified
in 64 of the total cohort of 69 patients (93%) at diagnosis.
In fact, because more than one highly sensitive LAIP could
be identified in some patients, a total of 150 LAIPs in 62
positive cases were defined. On the other hand, we failed
to identify a LAIP in five patients (7%). We successfully
applied the ‘empty space’ concept in 12 patients. The most
frequent LAIPs were CD34+hMICL+ , hMICL+CD34high and
CD123 + CD34+ (Table II).
Quantitation of differences in hMICL/CD123-based
LAIP-positive cells between AML and normal and
regenerating BM samples
A crucial issue in the optimization of a routine MRD marker
is the delineation of differences between leukaemic and nor-
mal and regenerating BM cells. We approached this issue by
employing the LD concept (Table II). As will appear, the
maximum LD from the median frequency in both normal
and regenerating BM allowed for identification of the three
most optimal LAIPs in the series. For normal BM these
were: hMICL+CD123high, Empty space (CD34 + AML), and
hMICL+CD34high and in regenerating BM: Empty space
(CD34 + AML), hMICL+CD123high, and empty space
(CD34- AML) in that order of maximal LD.
Comparison of MRD as measured by qPCR and by
hMICL/CD123 based MCF post induction
We directly compared MRD by the hMICL/CD123 assay and –
as gold standard –optimized qPCR assays (Fig 3). Here, 21
molecularly positive patients were evaluable for MRD post-
induction, three positive for a fusion transcript and 18 patients
had WT1 over expression. Relative MRD levels of the most
sensitive hMICL/CD123 LAIPs and standard MFC LAIPs were
compared separately to relative qPCR MRD levels. The corre-
lation between our standard MFC LAIPs (Table S1) and qPCR
was r = 0574 (P = 00065) and even stronger for the hMICL/
CD123 based assay r = 0676 (P = 0008).
Level of hMICL/CD123 as a prognostic test at first CR
evaluation
The level of LAIP post-induction was evaluated as a marker
for treatment response. When tabulating the levels of
hMICL/CD123 LAIPs, we found that of 13 patients with
hMICL/CD123 MRD levels above the median in regenerating
BM, 10 patients relapsed. Conversely, only one patient with
hMICL/CD123 MRD below the median in regenerating BM
relapsed (Fig 4). With an admittedly short period of observa-
tion, a statistically significant difference (P < 0001) in RFS
was detected, with patients with hMICL/CD123 LAIPs levels
below the median in regenerating BM less prone to relapse.
Validation of longitudinal monitoring of MRD by
hMICL/CD123 LAIPS in comparison to qPCR
To determine the value of the hMICL/CD123 MRD marker
in the follow-up phase, we monitored 15 patients longitudi-
nally (median number of MRD samplings = 3, range 3–6) by
relative hMICL/CD123-based MRD by MFC and compared
these results directly to relative qPCR MRD. We found that
these widely different methodologies yielded closely paralleled
MRD curves and kinetics (Fig 5).
Discussion
We have previously reported that the hMICL and CD123 anti-
gens were widely expressed and stable markers in more than
90% of AML samples. This contrasted to other surface proteins
routinely employed for AML immunophenotyping, because
these were not only less frequent at diagnosis but also prone to
change at relapse in up to 35% of cases (Oelschl€agel et al,
2000; Voskova et al, 2004; Larsen et al, 2012). Moreover, as
both hMICL and CD123 have been suggested as strong mark-
ers for LSCs (Jordan et al, 2000; van Rhenen et al, 2007b; Jin
et al, 2009), we have pursued the issue of the hMICL/CD123
markers in combination with CD45 and the stem cell antigens
CD34 and CD117 as an MFC MRD tool. Through spiking
experiments and by testing a prospective patient cohort, we
showed that this combination of MoAbs constituted a simple,
widely applicable MFC MRD tool. Regarding the specificity of
the LAIPs, high hMICL/CD123 MRD levels post-induction
were strongly predictive of relapse.
The CD34 antigen is a widely applied backbone in LAIP
identification due to its expression on immature cells. How-
ever, CD34 negativity of diagnostic samples has been
reported as high as 20-30% when employing a cut-off of 1%
(Al-Mawali et al, 2009; Taussig et al, 2010). In our series of
patients, 18/69 (26%) were classified as CD34- using this
threshold. Among those patients, we only failed to identify a
LAIP for MRD detection in one patient when applying the
hMICL/CD123-based approach. Thus, this combination of
antibodies paves the way for improved LAIP characterization
and MRD quantification by MFC in the otherwise poorly
described CD34- AML cases. Moreover, hMICL/CD123 im-
munophenotyping may be taken advantage of in cell sorting
experiments followed by molecular and cytogenetic analyses
and functional studies to better characterize LSCs in CD34-
AML. On-going molecular studies of FACS (fluorescent-acti-
vated cell sorting) sorted hMICL/CD123 LAIP-positive cells
MRD Detection in AML Using hMICL and CD123
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in our laboratory have confirmed that these populations are,
in fact, highly enriched for AML-related molecular aberra-
tions (data not shown).
In total, the search for LAIPs was positive in 93% of diag-
nostic AML samples when using the hMICL/CD123-based
combinations, with sensitivities down to 104. By inference,
the addition of more colours should undoubtedly allow for
further increased sensitivity and applicability, and reduce the
amount of BM necessary, as well as costs incurred and time
spent. At least four things should be kept in mind: Firstly,
the amount of labour and reagents using the present
approach are much less than the traditional one, which
involves multiple antibody combinations (Kern et al, 2010b;
Bene et al, 2011; van Dongen et al, 2012). Secondly, in rou-
tine MFC MRD assessment, it is recommended to determine
at least two independent LAIPs to circumvent the problem
of false negative results due to immunophenotypic shifts
(Kern et al, 2010a). As both hMICL and CD123 can be
detected with conserved antigen densities at relapse, this may
well allow for reducing the number of MoAbs and tubes used
(Langebrake et al, 2005; Larsen et al, 2012). Thirdly, our data
have pinpointed the potential importance of applying the
empty space – also termed the ‘different-from-normal’ –
concept (Lucio et al, 2001; Paietta, 2012a). While highly sen-
sitive in some of our patients, more are, nevertheless, needed
to conclusively determine the impact of empty space hMICL/
CD123 LAIPs in AML. Finally, the hMICL/CD123 assessment
is based on the detection of antigens associated with LSCs
(Majeti, 2010; Estey, 2012). This could lend an added bonus
of the approach due to its possible marking of cells thought
to selectively survive anti-leukaemia treatment. In fact, stan-
dard MFC panels may fail to detect persisting LSCs post-
therapy, which may explain treatment failure in otherwise
MFC MRD-negative patients (Bachas et al, 2012; Buccisano
et al, 2012).
It might be argued that, because LSC-directed MRD
quantification by MFC does not include all malignant cells,
this could lead to a lowering of sensitivity in terms of using
LD calculations in the search for the most optimal LAIP.
This was evidenced in our longitudinally tabulated log
changes of MRD in paralleled relative qPCR and MFC
analyses. While we did observe a striking parallelism, qPCR
performed better than MFC in this setting. However, this
does not in any way diminish the importance of the LSC
MFC assays, as the one presented here. In fact, the LSC
assays’ higher specificity and improved sensitivity due to
low background expression may offer a significant advan-
tage (van Rhenen et al, 2005; ten Cate et al, 2010). Differ-
ent MRD approaches are compared based on their
sensitivity, specificity and applicability, and results are
reported as continuous variables that may not be directly
comparable (e.g. log changes versus percentages of LAIP+
cells) (Paietta, 2012a). Irrespective of this, tandem perfor-
mance and comparison of these methodologies will ensure
better MRD coverage and facilitate the establishment of
method-specific thresholds and the translation of MRD
results into clinical decision making.
The assessment of MRD is a surrogate marker of treat-
ment efficacy that has prognostic impact, although formal
implementation of MRD assessment in the management of
AML patients is still in its infancy (Hourigan & Karp,
2013). In addition, the preferred platform for the measure-
ment of MRD is still a matter for debate. We have recently
suggested a context-driven application of MRD-methods
(Hokland et al, 2012). The MFC assays have the advantages
of wide applicability and short turnover time, and enable
the exact enumeration of LAIP-positive cells. On the other
hand, the fusion transcripts and somatically mutated
genes are the most sensitive and specific MRD targets and
can, together with overexpressed genes, be applied for
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monitoring MRD by qPCR. Additionally, new methods,
such as next generation sequencing, are fast gaining ground
(Kohlmann et al, 2013). How then to implement the
hMICL/CD123-based assay in a routine clinical setting? At
the present time this assay should not replace standard
LAIP marking. Although the sensitivity and applicability of
the assay is established, prospective evaluation in larger
patient cohorts are needed to further solidify its perfor-
mance, and establish clinical cut-off values and recommen-
dations on sampling frequencies.
In conclusion, we have defined an MFC assay employing
hMICL/CD123 in combination with CD34 and CD117,
which is comparable to qPCR. It should allow for simpler,
faster and more standardized MRD determination by MFC
than hitherto described assays due to LAIP coverage of more
than 90% of the patients with sensitivities down to 104 and
improve MRD assessment in CD34- AML.
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